Mitch C. Hill - 13 Feb 2023 Form 4 Insider Report for Inari Medical, Inc.

Role: Chief Financial Officer
Signature: /s/ Angela Ahmad, attorney-in-fact for Mitch C. Hill
Issuer symbol: N/A
Transactions as of: 13 Feb 2023
Net transactions value: -$683,173
Form type: 4
Filing time: 15 Feb 2023, 15:43:22 UTC
Previous filing: 13 Jan 2023
Next filing: 22 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NARI	Common Stock	Options Exercise	$2,970	+6,500	+12%	$0.4570^*	59,230	13 Feb 2023	Direct	F1
transaction	NARI	Common Stock	Sale	$294,927	-5,486	-9.3%	$53.76	53,744	13 Feb 2023	Direct	F1, F2
transaction	NARI	Common Stock	Sale	$54,868	-1,014	-1.9%	$54.11	52,730	13 Feb 2023	Direct	F1, F3
transaction	NARI	Common Stock	Sale	$303,696	-5,647	-11%	$53.78	47,083	13 Feb 2023	Direct	F1, F4
transaction	NARI	Common Stock	Sale	$32,652	-603	-1.3%	$54.15	46,480	13 Feb 2023	Direct	F1, F5, F6
holding	NARI	Common Stock						1,600	13 Feb 2023	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NARI	Stock Options (Right to Buy)	Options Exercise	$0	-6,500	-3.9%	$0.000000	159,477	13 Feb 2023	Common Stock	6,500	$0.4570	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022.
F2	This transaction was executed in multiple trades at prices ranging from $53.03 to $54.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	This transaction was executed in multiple trades at prices ranging from $54.03 to $54.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4	This transaction was executed in multiple trades at prices ranging from $53.08 to $54.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5	This transaction was executed in multiple trades at prices ranging from $54.10 to $54.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6	The balance includes 276 shares acquired under the Employee Stock Purchase Plan.
F7	Options vested with respect to 25% of the shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment thereafter.